Authors:
Ilani, T
Ben-Shachar, D
Strous, RD
Mazor, M
Sheinkman, A
Kotler, M
Fuchs, S
Citation: T. Ilani et al., A peripheral marker for schizophrenia: Increased levels of D-3 dopamine receptor mRNA in blood lymphocytes, P NAS US, 98(2), 2001, pp. 625-628
Authors:
Strous, RD
Pollack, S
Robinson, D
Sheitman, B
Lieberman, JA
Citation: Rd. Strous et al., Seasonal admission patterns in first episode psychosis, chronic schizophrenia, and nonschizophrenic psychoses, J NERV MENT, 189(9), 2001, pp. 642-644
Authors:
Zimmet, SV
Strous, RD
Burgess, ES
Kohnstamm, S
Green, AI
Citation: Sv. Zimmet et al., Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: A retrospective survey, J CL PSYCH, 20(1), 2000, pp. 94-98
Authors:
Green, AI
Zimmet, SV
Strous, RD
Schildkraut, JJ
Citation: Ai. Green et al., Clozapine for comorbid substance use disorder and schizophrenia: Do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?, HARV R PSYC, 6(6), 1999, pp. 287-296
Citation: Rd. Strous et al., Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features, AM J PSYCHI, 156(6), 1999, pp. 973-974